Erasca Inc (ERAS) Stock Price, Quote & News

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 465 6511

Website: www.erasca.com

Address:

3115 Merryfield Row, Suite 300, San Diego, United States

Iightning Dec. 4 at 11:34 PM

1ightning® Premium Options Alert (Actionable) Ticker: $ERAS Contract: Dec 19 $2.5C Entry: 0.88 Exit: 1.48 Return: +69.34% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

SuperGreenToday Dec. 4 at 12:06 PM

$ERAS Share Price: $3.30 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.99 – $1.23 Target Zone: $1.81 – $2.21 Potential Upside: 72% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Iightning Dec. 4 at 7:15 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ERAS Contract: Dec 19 $2.5C Entry: 1.10 Exit: 1.72 Return: +56.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Sw1ngb0t Dec. 3 at 10:28 PM

$PHVS $CCCC $GOSS $ERAS some newbs

0 · Reply

Iightning Dec. 2 at 1:37 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ERAS **Contract:** Dec 19 $5C **Entry:** 0.47 **Exit:** 0.74 **Return:** **+56.77% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Iightning Nov. 26 at 4:32 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.58 | Profit: 22.78% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 2:39 PM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.58 | Profit: 22.78% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:32 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.58 | Profit: 22.78% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 12:45 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.90 | Profit: 90.21% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.90 | Profit: 90.21% ROI | https://1ightning.com

0 · Reply

Erasca to Present at the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:01 PM EST - 22 days ago

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Erasca to Present at Upcoming Conferences in November

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Jun 2, 2025, 8:00 AM EDT - 6 months ago

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

May 29, 2025, 8:00 AM EDT - 6 months ago

Erasca to Present at Upcoming Investor Conferences in June

May 13, 2025, 4:05 PM EDT - 7 months ago

Erasca Reports First Quarter 2025 Business Updates and Financial Results

May 13, 2025, 8:00 AM EDT - 7 months ago

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 7, 2025, 8:00 AM EDT - 7 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

Apr 29, 2025, 4:05 PM EDT - 7 months ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Apr 25, 2025, 11:33 AM EDT - 7 months ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Mar 25, 2025, 4:31 PM EDT - 9 months ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 9 months ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Jan 31, 2025, 8:00 AM EST - 10 months ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 27, 2025, 12:09 AM EST - 11 months ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Nov 12, 2024, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 5, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

May 21, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 16, 2024, 8:02 PM EDT - 1 year ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:00 PM EDT - 1 year ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 8, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 7, 2024, 8:00 AM EDT - 1 year ago

Erasca to Present at the Bank of America Health Care Conference

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Mar 29, 2024, 11:11 AM EDT - 1 year ago

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Mar 27, 2024, 8:30 PM EDT - 1 year ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Jan 3, 2024, 8:00 AM EST - 2 years ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 8:00 AM EST - 2 years ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Nov 28, 2023, 8:00 AM EST - 2 years ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 9, 2023, 4:01 PM EST - 2 years ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at Upcoming Investor Conferences in November

Oct 10, 2023, 3:56 PM EDT - 2 years ago

Why Shares of Erasca Are Jumping Tuesday

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 28, 2023, 6:05 AM EDT - 2 years ago

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

AMGN BLUE CAT CSCO CVX DOW IBM

Aug 14, 2023, 3:22 PM EDT - 2 years ago

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

CVX PUMP

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Jun 22, 2023, 4:01 PM EDT - 2 years ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Jun 5, 2023, 4:01 PM EDT - 2 years ago

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

May 31, 2023, 8:00 AM EDT - 2 years ago

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 25, 2023, 5:00 PM EDT - 2 years ago

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

May 16, 2023, 8:00 AM EDT - 2 years ago

Erasca Further Strengthens Business Leadership with Two Key Promotions

May 15, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports First Quarter 2023 Financial Results and Business Updates

May 2, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

May 1, 2023, 8:00 AM EDT - 2 years ago

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

Apr 26, 2023, 5:00 PM EDT - 2 years ago

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Iightning Dec. 4 at 11:34 PM

1ightning® Premium Options Alert (Actionable) Ticker: $ERAS Contract: Dec 19 $2.5C Entry: 0.88 Exit: 1.48 Return: +69.34% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

SuperGreenToday Dec. 4 at 12:06 PM

0 · Reply

Iightning Dec. 4 at 7:15 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ERAS Contract: Dec 19 $2.5C Entry: 1.10 Exit: 1.72 Return: +56.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Sw1ngb0t Dec. 3 at 10:28 PM

$PHVS $CCCC $GOSS $ERAS some newbs

0 · Reply

Iightning Dec. 2 at 1:37 AM

0 · Reply

Iightning Nov. 26 at 4:32 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.58 | Profit: 22.78% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 2:39 PM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.58 | Profit: 22.78% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:32 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.58 | Profit: 22.78% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 12:45 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.90 | Profit: 90.21% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.90 | Profit: 90.21% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 1:35 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.90 | Profit: 90.21% ROI | https://1ightning.com

0 · Reply

_www_larval_com_ Nov. 19 at 3:47 PM

$ERAS has turned -4% lower to 1% (~816Kv) a moment ago, 11/21 options, follow for more volatility.

1 · Reply

Iightning Nov. 19 at 9:42 AM

1ightning® Options Trade Alert (Actionable) | Buy $ERAS Dec 19 $5 Call | Enter: $0.47 Exit: $0.90 | Profit: 90.21% ROI | https://1ightning.com

0 · Reply

makedatbread88 Nov. 17 at 5:42 PM

$ERAS niceeee ***FOLLOW ME for more winning calls!***

0 · Reply

JarvisFlow Nov. 14 at 2:19 PM

Guggenheim has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 3 → 5.

0 · Reply

Investor6 Nov. 13 at 2:27 PM

$ERAS Erasca press release (ERAS): Q3 GAAP EPS of -$0.11 in-line. Cash, cash equivalents, and marketable securities were $362.4 million as of September 30, 2025, compared to $440.5 million as of December 31, 2024. Erasca expects its cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2028.

0 · Reply

RunnerSignals Nov. 12 at 9:23 PM

Market Warriors on the Move! $CNTA $TRX.X $ERAS $RANI $CHGG started down but closed strong

0 · Reply

TheRealShortSqueezy Oct. 16 at 7:15 PM

$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS

2 · Reply

JarvisFlow Oct. 16 at 1:44 PM

Stifel has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 4.

0 · Reply

notreload_ai Oct. 16 at 1:14 PM

Stifel initiates $ERAS coverage with Buy rating and $4.X target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition. https://notreload.xyz/erasca-gets-buy-rating-cancer-drug-potential/

0 · Reply

Quantumup Oct. 15 at 8:29 PM

Stifel $RVMD: We are resuming coverage of Revolution Medicines (RVMD) with a Buy rating and $85 target price. $IMRX $ERAS $DAWN $BBOT We believe RVMD is on the cusp of majorly disrupting the PDAC standard of care - we expect other indications to follow in years to come. The TAM is massive, ~30% of all solid tumors have some type of RAS alteration. RVMD's first-in-class pan-RAS is poised to benefit from a substantial first-to-market advantage; nearest competitors are years behind. We model first revenue for RVMD in 1Q27 and global revenue of $11.3B by 2035. Sector specialists are in 2 camps on RVMD: (1) too expensive, or (2) still undervalued for PDAC opportunity alone. We expect that once the 2L PDAC Ph3 reads out in 2026, the game changes as the stock becomes attractive to a more diverse group of investors, and those currently on the sideline would be wise to take a stake sooner.

0 · Reply

QuantInsider Oct. 12 at 11:16 AM

What’s going on with $ERAS? Saw a big 7,072-contract ask-side sweep in those Jan 16 26 $2 calls on Oct 8 That’s about $842K at 172% IV Huge volume spike But with Morgan Stanley and BofA downgrades pushing it to a 2025 low, the risk is real Feels like early accumulation But I’m holding off Need to see if open interest grows next session and the call bid holds before thinking long Don’t jump the gun unless there’s follow-through in call OI and volume

0 · Reply

Market Cap	819.93M
Revenue (ttm)	0.00
Net Income (ttm)	-161.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,227,100
Avg Vol	1,922,370
Day's Range	N/A - N/A
Shares Out	283.71M
Stochastic %K	86%
Beta	1.16
Analysts	Strong Sell
Price Target	$4.14